ODX.L Regulatory News (ODX)

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Nigerian Ministry of Health approval for VISITECT® CD4 350 test

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Company has received approval from the Federal Ministry of Health ("MOH") to enable the VISITECT® CD4 350 test to be deployed in Nigeria.

Following a product evaluation in six geopolitical zones in Nigeria, co-ordinated by the National AIDS and Sexually Transmitted Infections Control Programme ("NASCP"), NASCP recommended to the MOH that the Company's VISITECT® CD4 350 test be adopted into the National HIV Control Programme as a rapid and instrument-free test device that provides actionable results at the point of care.

MOH approval means the Company's VISITECT® CD4 350 test is the first rapid and instrument-free CD4 test to be implemented throughout Nigeria in the care of people living with HIV. As announced on 2 December 2019, we have received initial orders from our distribution partner in Nigeria for 250,000 tests and we will now look to firm up a delivery schedule to determine what proportion of this demand can be shipped prior to the end of the financial year.

Colin King, CEO of Omega commented: "I am pleased that our test has been approved for use in Nigeria which was one of our key strategic aims and allows our unique point-of-care test to make a real difference to people living with HIV in Nigeria."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts: